This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.
The STAR Registry will collect patient-level clinical data on antithrombotic removal with CytoSorb. The decision to use CytoSorb in this clinical setting is based on the clinical rationale of mitigating the high risk of bleeding events that is directly linked to the presence of the antithrombotic agent. This registry is to capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb. Data of retrospective and prospective patients will be included in the registry. Safety will be assessed by collection of (at least possibly) device-related adverse events. Data collection is done up to 30 days post-operation.
Study Type
OBSERVATIONAL
Enrollment
1,000
Sorbent hemoperfusion system
Bleeding complications including requirements for transfusions and other blood products
Time frame: Assessed until postoperative day (POD) 3, date of ICU discharge, or date of death, whatever comes first; on average 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Universitätsklinikum Graz
Graz, Austria
RECRUITINGMedizinische Universität Innsbruck
Innsbruck, Austria
RECRUITINGKlinikum Klagenfurt am Wörthersee
Klagenfurt, Austria
RECRUITINGMedical University of Vienna
Vienna, Austria
RECRUITINGCentre Hospitalier Universitaire de Liège
Liège, Belgium, Belgium
RECRUITINGOLV ziekenhuis Aalst VZW
Aalst, Belgium
RECRUITINGCliniques Universitaires Saint-Luc
Brussels, Belgium
RECRUITINGUniversity Hospital Ghent
Ghent, Belgium
RECRUITINGEvangelisches Herzzentrum Coswig
Coswig, Germany
RECRUITINGHerzchirurgische Klinik Erlangen
Erlangen, Germany
RECRUITING...and 20 more locations